HCW

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022

Retrieved on: 
星期一, 五月 23, 2022
Diabetes, Inflammation, Company, U.S. Securities and Exchange Commission, Degenerative disease, Patient, NASDAQ, Masonic Cancer Center, Tissue, University of Minnesota, FDA, Neurodegeneration, IND, Conference, Forward-looking statement, University, Private Securities Litigation Reform Act, SEC, Cancer, HCW, CEO, Annual report, GLOBE, Pharmaceutical industry

MIRAMAR, Fla., May 23, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the Company) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, announced today that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will give a corporate presentation on May 25, 2022 at the H.C. Wainwright Annual Global Life Sciences Conference.

Key Points: 
  • MIRAMAR, Fla., May 23, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the Company) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, announced today that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will give a corporate presentation on May 25, 2022 at the H.C. Wainwright Annual Global Life Sciences Conference.
  • The presentation will be available on the HCW Biologics investor relations website beginning on Wednesday, May 25, 2022.
  • The invention of HCW Biologics two lead molecules, HCW9218 and HCW9302, was made via the TOBI discovery platform.
  • The FDA has also cleared HCW Biologics to initiate a Phase 1b clinical trial for HCW9218 in patients with advanced pancreatic cancer.

Cingulate to Present at H.C. Wainwright Global Investment Conference

Retrieved on: 
星期三, 五月 18, 2022
Anxiety, Precision Time Protocol, Public relations, Patient, NASDAQ, Cingulate cortex, Attention deficit hyperactivity disorder, Conference, Attention, ADHD, Technology, PTR, HCW, GLOBE, Pharmaceutical industry

ET, at the Fontainebleau Miami Beach Hotel,Miami, FL.

Key Points: 
  • ET, at the Fontainebleau Miami Beach Hotel,Miami, FL.
  • A live webcast of the presentation may be accessed at: HCW - Cingulate Live Presentation .
  • A replay will be available on the investor section of Cingulates website at Cingulate Events & Presentations for 90 days.
  • For more information visit Cingulate.com
    Head of Investor & Public Relations, Cingulate, Inc.

Trevena to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
星期三, 五月 18, 2022
CEO, Company, U.S. Securities and Exchange Commission, Patient, Migraine, Private Securities Litigation Reform Act, COVID-19, Epilepsy, TRV734, Nobel Prize, Trevena Inc, Trevena, Central nervous system disease, FDA, Research, CNS, Conference, Central nervous system, Maintenance, Pain, SEC, CFO, HCW, Security (finance), Risk, GLOBE, Pharmaceutical industry

If you have interest in participating in the H.C. Wainwright Global Investment Conference, please reach out to your HCW representative or register at the HCW events website.

Key Points: 
  • If you have interest in participating in the H.C. Wainwright Global Investment Conference, please reach out to your HCW representative or register at the HCW events website.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.
  • In addition, the forward-looking statements included in this press release represent the Companys views only as of the date hereof.
  • The Company anticipates that subsequent events and developments may cause the Companys views to change.

GreenBox POS to Participate in the H.C. Wainwright Global Investment Conference May 23-26, 2022

Retrieved on: 
星期三, 五月 18, 2022
NASDAQ, Efficiency, SAN, Company, Conference, GLOBE, HCW, CA, Cryptocurrency

SAN DIEGO, CA, May 18, 2022 (GLOBE NEWSWIRE) -- GreenBox POS (NASDAQ: GBOX) (GreenBox or the Company), an emerging and rapidly growing fintech company today announced that management will participate in the H.C. Wainwright Global Investment Conference.

Key Points: 
  • SAN DIEGO, CA, May 18, 2022 (GLOBE NEWSWIRE) -- GreenBox POS (NASDAQ: GBOX) (GreenBox or the Company), an emerging and rapidly growing fintech company today announced that management will participate in the H.C. Wainwright Global Investment Conference.
  • The hybrid conference will take place May 23-26, 2022 at the Fontainebleau Miami Beach Hotel and will include virtual and in-person participation.
  • GreenBox Chairman, Ben Errez, will give a Company presentation and be available for virtual one-on-one meetings with investors.
  • The Company's applications enable an end-to-end suite of turnkey financial products, fraud detection and improving the efficiency of handling large-scale commercial processing volumes for its merchant clients globally.

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
星期五, 五月 13, 2022
Diabetes, Inflammation, Company, Investment, Experimental biology, R, G&A, Research, U.S. Securities and Exchange Commission, Annual report, Degenerative disease, Patient, NASDAQ, Form 10-K, Masonic Cancer Center, Association, Tissue, FDA, Neurodegeneration, IND, Conference, United States Department of the Treasury, Microdeletion syndrome, Board, Forward-looking statement, University, Immunotherapy, Sale, Ageing, IPO, American Association, Cell, Private Securities Litigation Reform Act, SEC, Cellular senescence, HCW, CEO, GLOBE, Pharmaceutical industry, Vaccine, Online gambling, Cancer

MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the Company or HCW Biologics) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022.

Key Points: 
  • MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the Company or HCW Biologics) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022.
  • First Quarter 2022 Financial Results:
    Cash and cash equivalents: On March 31, 2022, the Companys cash balance was $18.1 million, short-term investments were $17.0 million and long-term investments were $9.8 million.
  • The invention of HCW Biologics two lead molecules, HCW9218 and HCW9302, was made via the TOBI discovery platform.
  • The FDA has cleared HCW Biologics to initiate a first-in-human Phase 1b clinical trial for HCW9218 in patients with advanced pancreatic cancer.

Conformis, Inc. to Participate in the H.C. Wainwright Global Investment Conference

Retrieved on: 
星期二, 五月 10, 2022
Health, NASDAQ, GLOBE, Dipterocarpus conformis, Arthralgia, Webcast, Knee, Patent, HCW, Joint, Conference, Solution, TMT, Investor, Online gambling, Medical device

The hybrid conference will take place May 23-26, 2022.

Key Points: 
  • The hybrid conference will take place May 23-26, 2022.
  • The conference will be held at the Fontainebleau Miami Beach Hotel and will include virtual and in-person participation.
  • Leading companies in life sciences, cryptocurrency/fintech, TMT, and cleantech are expected to participate.
  • Conformis management will participate virtually via an on-demand presentation which will be available starting on May 24, 2022 at 7:00 a.m.

HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists

Retrieved on: 
星期四, 五月 5, 2022
Masonic Cancer Center, Forward-looking statement, University, Tissue, IND, Company, Annual report, AAI, Patient, Neurodegeneration, Degenerative disease, FDA, Inflammation, Cancer, Diabetes, Form 10-K, HCW, Private Securities Litigation Reform Act, Fibroblast, Event, U.S. Securities and Exchange Commission, SEC, NK, Pharmaceutical industry

MIRAMAR, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammaging, that is, chronic, low-grade inflammation, and age-related diseases, is presenting two groups of novel immunotherapeutics created with its proprietary and powerful Tissue factOr-Based fusIon (TOBI™) discovery platform at the 105th Annual Meeting of the American Association of Immunologists (AAI), or Immunology 2022.

Key Points: 
  • The Company has combined deep understanding of disease-related immunology with its expertise in advanced protein engineering to develop the TOBI (Tissue factOr-Based fusIon) discovery platform.
  • The Company uses its TOBIdiscovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties.
  • The invention of HCW Biologics two lead molecules, HCW9218 and HCW9302, was made via the TOBI discovery platform.
  • The FDA has cleared HCW Biologics to initiate a first-in-human Phase 1b clinical trial for HCW9218 in patients with advanced pancreatic cancer.

HCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022

Retrieved on: 
星期二, 四月 19, 2022
University, Degenerative disease, Annual report, Ageing, CEO, See, Microdeletion syndrome, IND, NASDAQ, U.S. Securities and Exchange Commission, Cellular senescence, TIS, HCW, Molecular biology, Private Securities Litigation Reform Act, GLOBE, Masonic Cancer Center, Patient, Immunotherapy, Form 10-K, Inflammation, Conference, Experimental biology, Company, Neurodegeneration, SEC, Forward-looking statement, Animal, Tissue, Molecular Therapy, Diabetes, FDA, Cell, Inflammaging, Pharmaceutical industry, Cancer

MIRAMAR, Fla., April 19, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammaging, that is, chronic, low-grade inflammation, and age-related diseases, announced that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will speak at the Third Annual International Conference on Cell and Experimental Biology (“CEB-2022”) taking place in Boston, Massachusetts on April 18-20, 2022 (https://cellexpbiol.unitedscientificgroup.org).

Key Points: 
  • Dr. Wong will also share for the first time preclinical data showing that HCW9218 is a promising senolytic and senomorphic agent for age-related pathologies.
  • Thus, we believe HCW9218 can make chemotherapy cancer treatments work better with fewer side effects and extend the health span for cancer survivors.
  • The invention of HCW Biologics two lead molecules, HCW9218 and HCW9302, was made via the TOBI discovery platform.
  • The FDA has cleared HCW Biologics to initiate a first-in-human Phase 1b clinical trial for HCW9218 in patients with advanced pancreatic cancer.

Caesars Republic Scottsdale Luxury Hotel Announces Construction is Underway and Exclusive Event Reservations are Now Open for Q2 2024

Retrieved on: 
星期一, 四月 4, 2022
SVN, Caesars Entertainment, Silver, NASDAQ, National bank, MAC, Scottsdale Fashion Square, HCW, Restaurant, NYSE, Valley, Walker, Fort Dunlop, Camelback Mountain, Sun, Caesar, CZR, Caesars Entertainment (2020), Zions Bancorporation, Architecture, VIP, Harrah's Entertainment, Imagination, Pronto, Partnership, Hotel, Nightclub, Casino

SCOTTSDALE, Ariz., April 4, 2022 /PRNewswire/ -- National real estate development and property management company, HCW, is excited to announce above-ground construction is currently underway for the highly anticipated Caesars Republic Scottsdale luxury brand hotel.

Key Points: 
  • SCOTTSDALE, Ariz., April 4, 2022 /PRNewswire/ -- National real estate development and property management company, HCW , is excited to announce above-ground construction is currently underway for the highly anticipated Caesars Republic Scottsdale luxury brand hotel.
  • Prior to its opening, Caesars Republic Scottsdale is now accepting reservations for its indoor/outdoor event spaces that offers a one-of-a-kind experience unlike any other hotel in the Valley of the Sun with best-in-class amenities.
  • In partnership with Caesars Entertainment Corporation (NASDAQ: CZR) and Macerich (NYSE: MAC), Caesars Republic Scottsdale is designed to inspire the imagination and push creative boundaries.
  • Caesars Republic Scottsdale will also feature high ceilings, dedicated workspaces, and a top-of-the-line fitness center located across from the rooftop pool.

HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021

Retrieved on: 
星期一, 三月 28, 2022
Degenerative disease, National Cancer Institute, HCW, Neurodegeneration, Research, SEC, Publication, AbbVie, Cellular senescence, CEO, Intellectual, GLOBE, CD8, Insurance, University, Security (finance), Sale, Masonic Cancer Center, Conference, G&A, U.S. Securities and Exchange Commission, Income, Founder, IPO, CGMP, NASDAQ, Investment, Forward-looking statement, Clinical trial, Board, Invention, Board of directors, Prospectus, Abbott, Diabetes, Inflammation, Center, FDA, Patient, Company, Leadership, IND, Toxicology, Molecular Therapy, Cancer, Private Securities Litigation Reform Act, COVID-19, NCI-designated Cancer Center, Bifunctional, R, Pharmaceutical industry, Management, Review

MIRAMAR, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported recent business highlights and financial results for its fourth quarter and full year ended December 31, 2021.

Key Points: 
  • Dr. Hing C. Wong, the Founder and CEO of HCW Biologics, stated, We accomplished a number of significant achievements in the past year.
  • Year in Review Business Highlights:
    In the year ended December 31, 2021, the Company achieved several milestones:
    IPO.
  • Revenues: Revenues for the fourth quarter and year ended December 31, 2020 and 2021 were $4.1 million and none, respectively.
  • Research and development (R&D) expenses: R&D expenses for the fourth quarter ended December 31, 2020 and 2021 were $1.4 million and $1.5 million, respectively.